Q-omics provides the consensus-scored WASIR1 profile across patient tissues and cancer cell-line models. WASIR1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WASIR1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, WASIR1 RNA expression shows 6,505 significant pathway-activity associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, and ESCA as cancer lineages where WASIR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WASIR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WASIR1 survival associations across molecular data types. WASIR1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WASIR1 RNA expression–survival associations across cancer types. High WASIR1 expression shows unfavorable associations in KIRC, COAD, LIHC and LUAD, but favorable associations in BLCA and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WASIR1 RNA expression.
This table summarizes WASIR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for WASIR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WASIR1 shows lower tumor expression in KIRC and KICH and higher tumor expression in BLCA, LUSC, THCA and PRAD. The KIRC box plot shows higher WASIR1 RNA expression in normal versus tumor tissue (log2 FC = −0.087, t-test p < 0.001).
This table shows molecular features associated with WASIR1 in patient tissues and cancer cell lines. In patient samples, WASIR1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
